Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: medicine  family  safety  health  pharmaceuticals  teeth  children  cold  probiotics  multivu  8134881  golf  tim  herron  pga  tour  sports  pharmaceuticals  endo  feet  health  disease  multivu  8153851  deion  sanders  allergan  potox  health  men  beauty  cosmetic  style  multivu  8174251  alcon  medical  pharmaceuticals  lifestyle  cataract  surgery  treatment  sight  multivu  8068751  health  medicine  pharmaceuticals  gw  manufacturing  drugs  epileptic  treatment  pills  multivu  8109951  pharmaceutical  company  kaleo  auvi  q  injector  auto  medical  health  healthcare  multivu  7981051  science  talent  search  sponsorship  education  neil  degrasse  tyson  regeneron  competition  schools  multivu  7846351  pharmaceutical  research  manufacturing  health  cure  cancer  leukemia  cure  medical  multivu  7738431  jerry  punch  sports  mens  health  network  endo  pharmaceuticals  peyronies  disease  men  multivu  7752151  psa  greg  grunberg  epilepsy  seizures  sunovion  pharmaceuticals  awareness  health  multivu  7685991  johnson  johnson  biopharmaceutical  idea  pharma  neuroscience  medicine  health  innovation  multivu  7770851  healthprize  west  smartdose  electronic  wearable  auto  injector  confidose  medication  tracker  app  multivu  7625851 
Search // pharmaceutical
Results 1-12 of 32 for ' pharmaceutical ' (0 seconds)
Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, announced today that NFL analyst and philanthropist, Deion Sanders, the only athlete to play in both the Super Bowl™ and World Series™, will serve as a brand ambassador for BOTOX® Cosmetic. Harnessing Sanders’ trademark swagger, style and humor, Allergan also released two videos featuring Sanders sharing how he addressed his moderate to severe frown lines and crow’s feet with BOTOX® Cosmetic and showing men everywhere how the treatment may be right for them as well. To view the multimedia release go to: https://www.multivu.com/players/English/8174251-allergan-deion-sanders-botox/
Categories // Miscellaneous 
Added: 96 days ago by MultiVuVideos
Runtime: 5m49s | Views: 4 | Comments: 0
Not yet rated
 

 

 

Kaléo, a privately-held pharmaceutical company, today announced the AUVI-Q® (epinephrine injection, USP) Auto-injector will be available by prescription starting February 14th, and announced AUVI-Q AffordAbility, a first-of-its-kind access program for AUVI-Q. Through this new program, patients with commercial insurance, even those with high-deductible plans, will have an out-of-pocket cost of $0. For patients who do not have government or commercial insurance, and have a household income of less than $100,000, AUVI-Q will be available free of charge. In addition, the cash price for AUVI-Q is $360 and will be available to those patients without government or commercial insurance. Each AUVI-Q prescription includes two Auto-injectors and one Trainer for AUVI-Q. To view the multimedia release go to: http://www.multivu.com/players/English/7981051-auvi-q-epinephrine-auto-injector-access-and-availability-launch/
Categories // Miscellaneous 
Added: 328 days ago by MultiVuVideos
Runtime: 3m17s | Views: 7 | Comments: 0
Not yet rated
 

 

 

The Pharmaceutical Research and Manufacturers of America (PhRMA) today released new advertising as part of its “From Hope to Cures” campaign, highlighting the stories of rare blood and lung cancer survivors. The newest video in the collection features Matt, who was diagnosed nearly seven years ago with advanced non-small cell lung cancer. When he was diagnosed, he was given a slim chance of living up to five years. However, today Matt continues to lead an active life due to recent advancements in targeted gene therapies and innovations in cancer medicines. The latest print and digital ads feature Jamie, a vibrant woman diagnosed 15 years ago with chronic myelogenous leukemia (CML). Watching her son grow up was a primary focus for her, and she’s been able to continue to do that and so much more. Thanks to advancements in CML treatments, today she maintains her sense of humor and imparts an infectious joy on those who meet her. Earlier this year, the first collection of digital and print ads was released featuring Rhys, a five-year-old living with type 1 diabetes and celiac disease. Unveiled alongside the advertising was a video, titled “We’re Fighting Back,” which features both Rhys and Jamie, as well as Jen, a researcher who wakes up every day working to find new treatments and cures for patients. To view the multimedia release go to: http://www.multivu.com/players/English/7738431-phrma-from-hope-to-cures/
Categories // Miscellaneous 
Added: 605 days ago by MultiVuVideos
Runtime: 0m30s | Views: 119 | Comments: 0
Not yet rated
 

 

 

The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running. The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it? The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia). To view the multimedia release go to: http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/
Categories // Miscellaneous 
Added: 657 days ago by MultiVuVideos
Runtime: 3m36s | Views: 159 | Comments: 0
Not yet rated
 

 

 

West Pharmaceutical Services, Inc. (NYSE: WST) and HealthPrize Technologies, LLC, today announced the completion of the first two phases of their four-phase strategic collaboration. The companies are working to integrate HealthPrize’s Software-as-a-Service (SaaS) medication adherence and patient-engagement platform with West’s injectable drug delivery systems to provide an end-to-end connected health solution for pharmaceutical companies and the patients they serve. The combined offering will provide voluntary, electronically connected drug delivery systems that track when patients take their medication. The HealthPrize system engages and educates patients to increase adherence and medical literacy, rewarding interaction and compliance with prescribed treatment plans, and contributing to better health outcomes. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7625851-west-pharma-healthprize-tech-collaboration/
Categories // Business  Science and Technology 
Added: 818 days ago by MultiVuVideos
Runtime: 3m20s | Views: 184 | Comments: 0
Not yet rated
 

 

 

CPhI Worldwide, organised by UBM EMEA, formally launches a new partnership with international charity Global Angels, to help promote its efforts and encourage support from the pharmaceutical industry. The goal is to harness CPhI’s global reach to actively deliver support and funds from inside the pharma industry to Global Angels – a charity that partners with innovative projects to deliver tangible, life saving results in developing countries. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7522851-cphi-agreement-global-angels/
Categories // People and Blog  Business 
Added: 950 days ago by MultiVuVideos
Runtime: 3m15s | Views: 200 | Comments: 0
Not yet rated
 

 

 

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
Added: 967 days ago by MultiVuVideos
Runtime: 3m35s | Views: 257 | Comments: 0
Not yet rated
 

 

 

Patients and scientists from across the country are featured in the latest “From Hope to Cures” ad campaign launched today by the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents the country’s leading biopharmaceutical researchers and biotechnology companies. This continuation of PhRMA’s “From Hope to Cures” campaign, first launched in January 2014, highlights the value biopharmaceutical innovation provides to patients, society and the economy. The latest ad campaign, featuring print, radio and digital advertising, highlights the stories of patients who benefit from the medicines developed by biopharmaceutical companies and the scientists who work every day to develop life-saving treatments and cures. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350552-phrma-from-hope-to-cures/
Added: 1017 days ago by MultiVuVideos
Runtime: 2m5s | Views: 261 | Comments: 0
Not yet rated
 

 

 

Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations. The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7350554-phrma-report-innovation-rare-diseases/
Categories // People and Blog 
Added: 1021 days ago by MultiVuVideos
Runtime: 2m6s | Views: 303 | Comments: 0
Not yet rated
 

 

 

An injury ends Laura Nelson’s career as a surgeon. Now, as Vice President of a pharmaceutical company, Laura works to finalize the approval of a groundbreaking new drug. But her efforts are being thwarted by a malicious FDA employee who will stop at nothing to prevent the approval, and Laura is standing directly in his path. Find out more about the author here- http://patriciagussin.com/ and check out the book here http://oceanviewpub.com/after-the-fall/. After the Fall by Patricia Gussin. Thriller
Categories // Miscellaneous 
Added: 1034 days ago by cosproductions
Runtime: 1m-0s | Views: 245 | Comments: 0
     
 

 

 

Advanced technology has the power to transform healthcare, a world leader in the field of genomicsDr Leroy Hood, has said ahead of the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain. To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7430051-dr-leroy-hood-astellas-debate/
Added: 1050 days ago by MultiVuVideos
Runtime: 3m22s | Views: 246 | Comments: 0
Not yet rated
 

 

 

Personalised Medicine is the future of cancer treatment, but it presents major challenges for doctors and health services, the President of the European Society of Medical Oncology has said. Professor Rolf Stahel was speaking ahead of the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain. To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7430351-professor-rolf-stahel-astellas-debate/
Added: 1051 days ago by MultiVuVideos
Runtime: 2m58s | Views: 244 | Comments: 0
Not yet rated
 

 

 

Page 1 of 3  |  Go to page    Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2017 ClipMoon.com. All rights reserved.